The ideas and opinions expressed in IASLC Lung Cancer News do not necessarily reflect those of the International Association for the Study of Lung Cancer. The mention of any product, service, or therapy in this website should not be construed as an endorsement. Appropriate treatment for patients is the responsibility of their treating physicians and other health-care providers who rely on independent experience and knowledge of the patient. The appropriate medical literature and current product information should be checked by readers concerning verification of dosage, method, and duration of administration, or contraindications. The International Association for the Study of Lung Cancer accepts no responsibility for any injury or damage to person or persons arising out of or related to any errors, omissions, or use of material contained in this website.
By Jarushka Naidoo, MB, BCH Posted: April 1, 2019 The U.S. Food and Drug Administration (FDA) has approved immune checkpoint inhibitors for multiple cancer types, including stage...